Program
iptacopan
Also written as “Iptacopan”, “LNP023” and “Iptacopan (LNP023)”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome · Proteinuria · Macular Degeneration, led by Novartis.
Drug pageIptacopan: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 2512 open or running | phase 3since May 3, 2019 | Nov 30, 2017 | Dec 30, 2026phase 2 · NCT06388941 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 10 earlier studies, Nov 30, 2017 to Feb 5, 2021.
- Dec 9, 2019Named iptacopanINNProposed as its International Nonproprietary Name in WHO's List 122 · before, LNP023
- Mar 23, 20212 phase 3 studiesNCT04817618, NCT04820530
- May 7, 2021Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT04889430 · 34 enrolled · United States, Brazil, China and more
- Sep 28, 2021Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05086744 · 19 enrolled · United States, Germany, Italy and more
- Oct 13, 2021Phase 1 study in Hepatic ImpairmentNCT05078580 · 38 enrolled · United States
- Jan 28, 2022Phase 2 study in Macular DegenerationNCT05230537 · 168 enrolled · United States, China, Puerto Rico and more
- Nov 18, 2022Phase 3 study in Hemoglobinuria, ParoxysmalNCT05630001 · 52 enrolled · United States, France, Germany and more
- Feb 23, 2023Phase 3 study in ProteinuriaNCT05755386 · 106 planned · United States, Argentina, Brazil and more
- Mar 21, 2023Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT05795140 · 65 planned · Brazil, China, Czechia and more
- Jun 29, 2023Phase 3 study in Atypical Hemolytic Uremic SyndromeNCT05935215 · 50 planned · China, France, Germany and more
- Feb 12, 2024Phase 3 study in Myasthenia GravisNCT06517758 · 146 enrolled · United States, Argentina, Australia and more
- Apr 17, 2024Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06388941 · 84 enrolled · United States, Argentina, Australia and more
- Jan 21, 2025Phase 2 study in Glomerulonephritis, IGANCT06797518 · 20 planned · United States, Argentina, Israel and more
- Mar 31, 2025Phase 3 study in Hemoglobinuria, ParoxysmalNCT06934967 · 12 planned · United States, Brazil, Colombia and more
- May 20, 2025Phase 3 study in Glomerulonephritis, IGANCT06994845 · 31 planned · United States, Argentina, Australia and more
Ahead
- Dec 30, 2026Primary completion: phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06388941
- Jan 29, 2027Primary completion: phase 3 study in ProteinuriaNCT04817618
- Apr 30, 2027Primary completion: phase 3 study in Myasthenia GravisNCT06517758
- Oct 18, 2027Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalNCT04747613
TargetBeta
“Complement factor B inhibitor; Complement factor B inhibitor”ChEMBL 37, by rule
Other programs on CFB
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06994845Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Recruiting | Jun 28, 2030 | 31 |
| NCT06934967Hemoglobinuria, Paroxysmal · United States, Brazil, Colombia and more | 3 | Recruiting | Oct 14, 2031 | 12 |
| NCT06797518Glomerulonephritis, IGA · United States, Argentina, Israel and more | 2 | Recruiting | Nov 27, 2027 | 20 |
| NCT06388941Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States, Argentina, Australia and more | 2 | Active, not recruiting | Dec 30, 2026 | 84 |
| NCT06517758Myasthenia Gravis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 30, 2027 | 146 |
| NCT05935215Atypical Hemolytic Uremic Syndrome · China, France, Germany and more | 3 | Recruiting | Jul 21, 2028 | 50 |
| NCT05795140Atypical Hemolytic Uremic Syndrome · Brazil, China, Czechia and more | 3 | Recruiting | Jul 16, 2032 | 65 |
| NCT05755386Proteinuria · United States, Argentina, Brazil and more | 3 | Recruiting | Oct 27, 2028 | 106 |
| NCT05630001Hemoglobinuria, Paroxysmal · United States, France, Germany and more | 3 | Completed | Oct 17, 2024 | 52 |
| NCT05230537Macular Degeneration · United States, China, Puerto Rico and more | 2 | Completed | Aug 19, 2026 | 168 |
| NCT05078580Hepatic Impairment · United States | 1 | Completed | Jun 20, 2022 | 38 |
| NCT05086744Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Italy and more | 2 | Terminated | Sep 20, 2023 | 19 |
| NCT04889430Atypical Hemolytic Uremic Syndrome · United States, Brazil, China and more | 3 | Completed | Apr 11, 2026 | 34 |
| NCT04820530Hemoglobinuria, Paroxysmal · China, France, Germany and more | 3 | Completed | Nov 2, 2022 | 40 |
| NCT04817618Proteinuria · United States, Argentina, Belgium and more | 3 | Recruiting | Jan 29, 2027 | 98 |
| NCT04747613Hemoglobinuria, Paroxysmal · United States, Brazil, China and more | 3 | Active, not recruiting | Oct 18, 2027 | 208 |
| NCT04557462Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Recruiting | Dec 4, 2030 | 540 |
| NCT04578834Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Completed | Sep 19, 2025 | 517 |
| NCT04558918Hemoglobinuria, Paroxysmal · United States, Brazil, Czechia and more | 3 | Completed | Sep 26, 2022 | 97 |
| NCT04154787Glomerulonephritis, Membranous · Argentina, China, Czechia and more | 2 | Terminated | Jan 20, 2023 | 37 |
| NCT03955445Glomerulonephritis, Membranoproliferative · United States, Argentina, Brazil and more | 3 | Recruiting | May 30, 2036 | 225 |
| NCT03896152Hemoglobinuria, Paroxysmal · Korea, Republic of, Malaysia, Singapore and more | 2 | Completed | Apr 7, 2020 | 13 |
| NCT03832114Glomerulonephritis · United States, France, Germany and more | 2 | Completed | Apr 23, 2021 | 27 |
| NCT03439839Hemoglobinuria, Paroxysmal · France, Germany, Italy | 2 | Completed | Apr 22, 2020 | 16 |
| NCT03373461Glomerulonephritis, IGA · Argentina, Australia, Belgium and more | 2 | Completed | Dec 29, 2020 | 112 |
How it is read
Names in the registry
- “Iptacopan”, 12 entries
- “LNP023”, 9 entries
- “iptacopan”, 4 entries
- “Iptacopan (LNP023)”, 2 entries
- “Iptcaopan 200 mg”, 1 entry
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 7 studies
- Glomerulonephritis, IGA, 5 studies
- Atypical Hemolytic Uremic Syndrome, 3 studies
- Proteinuria, 2 studies
- Macular Degeneration, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.